This brand name is authorized in Austria, Brazil, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.
The drug PHOXILIUM contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
M4I0D6VV5M - CALCIUM CHLORIDE
|
|
Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat. |
|
2
|
UNII
660YQ98I10 - POTASSIUM CHLORIDE
|
|
Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism. |
|
3
|
UNII
02F3473H9O - MAGNESIUM CHLORIDE
|
4
|
UNII
451W47IQ8X - SODIUM CHLORIDE
|
|
Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue. |
|
5
|
UNII
8MDF5V39QO - SODIUM BICARBONATE
|
|
Sodium bicarbonate has antacid properties. Sodium bicarbonate causes neutralisation of gastric acid with the production of carbon dioxide. |
|
6
|
UNII
22ADO53M6F - SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| PHOXILIUM Solution for haemodialysis / haemofiltration | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| B05ZB | Hemofiltrates | B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05Z Hemodialytics and hemofiltrates |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 503220110030707 |
| EE | Ravimiamet | 1334786 |
| ES | Centro de información online de medicamentos de la AEMPS | 71309 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 133384 |
| FR | Base de données publique des médicaments | 64119056 |
| GB | Medicines & Healthcare Products Regulatory Agency | 324870 |
| HK | Department of Health Drug Office | 61168 |
| HR | Agencija za lijekove i medicinske proizvode | HR-H-682219500 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1029981 |
| MT | Medicines Authority | MA1277/03001 |
| NZ | Medicines and Medical Devices Safety Authority | 15830 |
| PL | Rejestru Produktów Leczniczych | 100222810 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W66877001, W66877002, W66877003, W66877004 |
| SG | Health Sciences Authority | 15730P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8681413881466 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.